Press ReleasesWISeSat.Space and SEALSQ Launch New Satellite with SpaceX, Enabling the First-Ever DePIN from Space, and Advancing Quantum-Safe Space Communications By globenewswire June 23, 2025 0 0 WISeSat.Space and SEALSQ Launch New Satellite with SpaceX, Enabling the First-Ever DePIN from Space, and Advancing Quantum-Safe Space Communications Geneva, Switzerland, June 23, 2025 (GLOBE NEWSWIRE) — Courtesy of SpaceX Source: https://www.globenewswire.com/news-release/2025/06/23/3103896/0/en/WISeSat-Space-and-SEALSQ-Launch-New-Satellite-with-SpaceX-Enabling-the-First-Ever-DePIN-from-Space-and-Advancing-Quantum-Safe-Space-Communications.html TagscommunicationsNasdaq:LAESNasdaq:LAESVnewsSAFEsatellitesourcespaceSpaceXVGG794831062 Previous articleLysander Funds Limited annonce des réductions des frais de gestion, le remplacement d’un gestionnaire de portefeuille et la modification du niveau de risque de certains fondsNext articleOrcoda Transforms Waipā District Council’s Fleet Management, Driving Efficiency and Sustainability globenewswire Dizal’s ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations July 3, 2025 ASIA’S 50 BEST BARS 2025 REVEALS THE ESTABLISHMENTS RANKED ON THE EXTENDED 51-100 LIST July 3, 2025 ASIA’S 50 BEST BARS 2025 REVEALS THE ESTABLISHMENTS RANKED ON THE EXTENDED 51-100 LIST July 3, 2025 Blokees Becomes Exclusive Strategic Partner of “Journey of Light: A Glimpse into Ultraman’s 60th Anniversary” Exhibition July 3, 2025 First AML expands Tranche 2 leadership in Australia following major client wins across law and real estate July 3, 2025 Lake Chelan Health enters into Prime Vendor agreement with Medline July 3, 2025 Recent News First AML expands Tranche 2 leadership in Australia following major client wins across law and real estate ASIA’S 50 BEST BARS 2025 REVEALS THE ESTABLISHMENTS RANKED ON THE EXTENDED 51-100 LIST Dizal’s ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations